Welcome to our dedicated page for Aurinia Pharmace SEC filings (Ticker: AUPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Canadian‑incorporated biopharmaceutical issuer listed in the United States. Aurinia files annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K, along with exhibits such as earnings releases and investor presentations.
Recent Form 8‑K filings referenced in the available data show how Aurinia uses current reports to furnish quarterly financial results, updates on its share repurchase plan and key clinical developments. For example, the company has filed 8‑Ks to furnish earnings releases for quarters ended March 31, June 30 and September 30, 2025, and to report positive Phase 1 results for aritinercept (AUR200), its dual BAFF and APRIL inhibitor. These filings often attach press releases and presentations as exhibits, providing additional context on revenue, net product sales of LUPKYNIS (voclosporin), license and collaboration revenue, and operating expenses.
Through its periodic reports, Aurinia discloses condensed consolidated balance sheets, statements of operations and cash flows, detailing items such as cash, investments, inventory, lease liabilities, deferred revenue and shareholders’ equity. Investors analyzing AUPH can use 10‑K and 10‑Q filings to review the company’s financial position, revenue composition between LUPKYNIS net product sales and collaboration income, and risk factor discussions related to its autoimmune disease focus.
On Stock Titan, these SEC filings are complemented by AI‑powered summaries that highlight the main points of lengthy documents, helping readers quickly identify changes in revenue, profitability, cash flows or capital allocation, such as the expansion of a share repurchase plan. Real‑time updates from EDGAR ensure that new Aurinia 10‑K, 10‑Q, 8‑K and related exhibits, as well as insider transaction reports on Form 4 when filed, are surfaced promptly with simplified explanations for easier review.
Aurinia Pharmaceuticals Inc. plans to acquire Kezar Life Sciences through a tender offer at $6.955 in cash per share plus one non-transferable contingent value right (CVR) for each Kezar share. After the offer, a follow-on merger will make Kezar a wholly owned Aurinia subsidiary under Delaware’s Section 251(h) process.
The CVR will give Kezar stockholders potential additional cash tied to Kezar’s closing net cash above $50.0 million, proceeds from existing Enodia and Everest agreements, and future monetization or development of zetomipzomib and other legacy assets over up to 10 years. A key Kezar holder owning about 9.0% of the stock has agreed to tender its shares, and closing is targeted for the second quarter of 2026, subject to minimum tender, net cash and other customary conditions.
Aurinia Pharmaceuticals Inc. disclosed that Chief Operating Officer Ryan Cole filed an initial statement of beneficial ownership on Form 3. This filing formally registers him as a reporting person for the company’s equity under securities regulations and establishes the baseline for any future insider transaction reports.
Aurinia Pharmaceuticals Inc. disclosed that Michael S. Hearne, its Chief Financial Officer, filed an initial Form 3 as a reporting person. This filing establishes his insider status for future ownership and transaction reporting but does not list any specific share holdings or recent trades.
Tang Capital Management, Kevin Tang and affiliated funds report beneficial ownership of 12,229,500 Aurinia Pharmaceuticals common shares, representing 9.2% of the class. This stake is based on 132,970,979 common shares outstanding as of February 25, 2026. The amendment also notes that Kevin Tang was appointed Chief Executive Officer of Aurinia Pharmaceuticals on March 23, 2026.
Aurinia Pharmaceuticals Inc. announced a major management transition, appointing Kevin Tang, currently Chair of the Board, as Chief Executive Officer and principal executive officer effective March 23, 2026. Tang has a long background in life sciences investing and biotech leadership and has elected to receive no salary, bonuses, equity awards or other compensation from Aurinia.
The Board also appointed Ryan Cole as Chief Operating Officer and Michael Hearne as Chief Financial Officer, principal financial officer and principal accounting officer, each with a $300,000 annual base salary, a target bonus equal to 50% of base salary, and a new hire option to purchase 150,000 Aurinia common shares. On March 20, 2026, prior officers including CEO Peter Greenleaf, COO Matthew Donley, CMO Gregory Keenan and CFO Joseph Miller ceased serving as officers, and Greenleaf resigned from the Board on March 21, 2026 but will consult for three months at $600 per hour to support the transition.
The Board created a new Lead Independent Director role and elected current independent director Craig Johnson to that position to help coordinate independent director activities and serve as liaison with the Chair and senior management.
Aurinia Pharmaceuticals Inc. reported that SVP and Chief Medical Officer Greg Keenan had 8,069 shares of Common Stock withheld on March 6, 2026 to cover tax obligations when restricted stock units vested. These shares were valued at $14.32 per share for this tax-withholding calculation. After this routine withholding, Keenan directly holds 154,449 common shares, showing he maintains a substantial equity position in the company.
Aurinia Pharmaceuticals Inc. director-associated entities reported significant open-market purchases of common shares. Limited partnerships associated with Kevin Tang bought a total of 900,000 common shares of Aurinia between February 27 and March 3, 2026, in a series of indirect transactions labeled “By LP.”
The purchases were executed at weighted-average prices around the mid-teens per share, with footnotes stating that the trades occurred in multiple transactions within ranges such as $13.51–$14.23 and several other bands in the low-to-mid $14 area. Following these buys, entities associated with Tang were reported as beneficially owning over 12 million Aurinia common shares.
Tang Capital Management and affiliates have updated their ownership disclosure for Aurinia Pharmaceuticals Inc. common shares. As of this amendment, the reporting group beneficially owns 12,229,500 common shares, representing 9.2% of Aurinia’s outstanding stock based on 132,970,979 shares as of February 25, 2026.
Since March 4, 2025, the reporting persons spent approximately $26.3 million to purchase 2,200,000 Aurinia common shares in open‑market transactions in the ordinary course of business. Voting and dispositive power over these shares is shared among Tang Capital Management, Tang Capital Partners entities and Kevin Tang under a joint filing arrangement.
Aurinia Pharmaceuticals Inc. reported insider equity activity by Chief Financial Officer Joseph M. Miller. On February 27, 2026, he received a grant of 95,700 employee stock options with an exercise price of $0.0000 per share and an award of 57,229 shares of common stock at no cost. The options vest one-third after twelve months from the grant date, with the remaining two-thirds vesting in twenty-four equal monthly installments.
Each performance right associated with these awards represents a contingent right to receive one common share, vesting in four tranches as the share price reaches progressively higher targets, each with a one-year retention period. On March 2, 2026, 37,511 common shares at $14.21 per share were withheld as a tax-withholding disposition to satisfy tax obligations upon vesting of restricted stock units, leaving Miller with 576,421 directly held common shares.
Aurinia Pharmaceuticals Inc. Chief Operating Officer Matthew Maxwell Donley reported equity compensation and related tax withholding transactions. On February 27, 2026, he received a grant of 97,256 employee stock options at an exercise price of $0.00 per share and a grant of 58,160 shares of common stock at no cost, both held directly.
Following the stock award, his directly held common stock position increased to 721,060 shares. On March 2, 2026, 40,761 common shares valued at $14.21 per share were disposed of through a tax-withholding disposition to satisfy tax obligations upon vesting of restricted stock units, leaving 680,299 common shares held directly.